Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Four-month-old infant with chronic granulomatous disease and invasive aspergillosis with bone involvement.
Biomedica
December 2024
Laboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Ciudad de México, México.
Chronic granulomatous disease is the inborn error of immunity with the highest frequency of invasive aspergillosis. In this context, invasive aspergillosis is frequent in adolescence, with rare cases before one year of age. We present a case of chronic granulomatous disease and invasive aspergillosis in a four-month-old infant.
View Article and Find Full Text PDFOccurrence of biofilm forming fungal species and in vitro evaluation of anti-biofilm activity of disinfectants used in drinking water.
Vet Res Forum
December 2024
Department of Microbiology, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Türkiye.
Fungal contamination in drinking water has garnered considerable attention over the past few decades, especially considering the detrimental consequences of pathogenic fungal species on both human and animal health. The formation of biofilms by certain species is a considerable factor contributing to the emergence of severe fungal infections. This research was designed to isolate and identify fungi, particularly those capable of forming biofilms from 150 samples of drinking water sourced from various locations.
View Article and Find Full Text PDFPosaconazole for Prevention of COVID-19-Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients: A European Multicentre Case-Control Study (POSACOVID).
Mycoses
January 2025
Division of Infectious Diseases, Department of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Medical University of Graz, Graz, Austria.
Background: This study investigated the impact of posaconazole (POSA) prophylaxis in COVID-19 patients with acute respiratory failure receiving systemic corticosteroids on the risk for the development of COVID-19-associated pulmonary aspergillosis (CAPA).
Methods: The primary aim of this prospective, multicentre, case-control study was to assess whether application of POSA prophylaxis in mechanically ventilated COVID-19 patients reduces the risk for CAPA development. All consecutive patients from centre 1 (cases) who received POSA prophylaxis as standard-of-care were matched to one subject from centre 2 and centre 3 who did not receive any antifungal prophylaxis, using propensity score matching for the following variables: (i) age, (ii) sex, (iii) treatment with tocilizumab and (iv) time at risk.
Performance of LDBio Aspergillus ICT IgM/IgG Lateral Flow Assay in Diagnosing Chronic Pulmonary Aspergillosis in Community Versus Hospital Setting.
Mycopathologia
January 2025
Doodhadhari Burfani Hospital, Haridwar, Uttarakhand, India.
Background: LDBio immunochromatographic lateral flow assay, a point-of care test, detects IgM/IgG antibodies against Aspergillus fumigatus (LDBio-ALFA). LDBio-ALFA has been evaluated for diagnosing chronic pulmonary aspergillosis (CPA) in hospital patients, though its efficacy in field settings remains unexamined.
Objective: Our primary objective was to assess the diagnostic accuracy of LDBio-ALFA in diagnosing CPA in a field and a hospital cohort.
The Molecular Basis of the Intrinsic and Acquired Resistance to Azole Antifungals in .
J Fungi (Basel)
November 2024
Sir John Walsh Research Institute, Faculty of Dentistry, University of Otago, Dunedin 9016, New Zealand.
is intrinsically resistant to the widely used antifungal fluconazole, and therapeutic failure can result from acquired resistance to voriconazole, the primary treatment for invasive aspergillosis. The molecular basis of substrate specificity and innate and acquired resistance of to azole drugs were addressed using crystal structures, molecular models, and expression in of the sterol 14α-demethylase isoforms AfCYP51A and AfCYP51B targeted by azole drugs, together with their cognate reductase AfCPRA2 and AfERG6 (sterol 24-C-methyltransferase). As predicted by molecular modelling, functional expression of CYP51A and B required eburicol and not lanosterol.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!